



07-16-07

1Fu

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/587,792
Filing Date	31 July 2006
First Named Inventor	Lopez Rodriguez, M., et al
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	6102-000031/US/NP

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)☐ Fee Transmittal Form☐ Fee Attached☐ Amendment / Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/ Incomplete Application☐ Response to Missing Parts under 37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a Provisional Application☐ Power of Attorney, Revocation Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ After Allowance Communication to Technology Center (TC)☐ Appeal Communication to Board of Appeals and Interferences☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s)
(please identify below):

Form 1449

IDS Documents

Certificate of Mailing

Return Postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name Harness, Dickey & Pierce, P.L.C.

Signature

Printed name J. Timothy Keane

Date

13 July 2007

Reg. No.

27,808

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name Daisy Manning

Express Mail Label No.

EV 844115539 US

Signature

Date

13 July 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.5. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Attorney Ref. 6102-000031/US

Serial No: 10/587,792

Title: Diaza- or Thiazadione Derivatives with Neuroprotective Activity

Filed: July 31, 2006

Mail Express No. EV 844115539 US

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on 13 July 2007

Date



Signature

Daisy Manning

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted .
Transmittal (1 page)
IDS Statement (5 pages) in duplicate
Form 1449 (7 pages)
IDS Documents 76

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Lopez Rodriguez, M., *et al.*
Serial No: 10/587,792
Filed: 31 July 2006
Title: DIAZA- OR THIAZADIONE DERIVATIVES WITH
NEUROPROTECTIVE ACTIVITY
Group Art Unit: TBA
Examiner: TBA
Confirmation No: 5328
Attorney Docket: 6102-000031/US/NP
Client Ref. No.: CEPA II

13 July 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS, AND OTHER INFORMATION

The patents, publications and other information requested to be considered by the Office (except unpublished U.S. patent applications) are listed on Form 1449 attached hereto.

II. COPIES

A. ☒ Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office; (iii) each unpublished U.S. application listed below in Section IV (i.e., including the specification, claims, and any drawing of the application, or that portion of the application which caused it to be listed,

including any claims directed to that portion), except for such applications filed on or after June 30, 2003, pursuant to the Waiver of the Copy Requirement in 37 C.F.R. 1.98 (OG Notice dated October 19, 2004); and (iv) all other information or that portion which caused it to be listed.

B. ☐ Any patents, publications or other information which are listed on Form 1449 or on the copies of PTO-892, but which are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Serial Number

U.S. Filing Date

C. ☐ This is a PCT application in the entry of the National Phase in the United States. A copy of the International Search Report is attached for the Examiner's information. The documents listed on the International Search report are listed on the attached Form 1449 for consideration by the Examiner and for listing on any patent resulting from this application. If the International Search report was from the US, EPO, or JPO search authorities, copies of these references should have been supplied to the USPTO under the trilateral agreement and are believed to be in the file of the above-identified application. (MPEP 1893.03(g).)

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

A. ☒ Except as may be indicated below in (B), all of the patents, publications or other information are in the English language (concise explanation not required).

B. ☒ A concise explanation of the relevance of each patent, publication or other information listed that is not in the English language is as follows (see 37 C.F.R. § 1.98(a)(3)):

1. ☐ See the attached foreign patent office communication from a counterpart foreign application:

2. ☒ English translations are provided:

English language abstracts are provided for: WO 1996/06846 A1, WO 1997/35860 A1, and WO 1999/15527 A1.

English language counterparts are provided by the applicant for: ES 2094690 A1 and ES 2154605 A1.

English language counterparts are provided for: EP 0352613 B1, ES 2052829 T3, WO 2003/029250 A1, ES 2199086 A1, WO 2004/014915 A1, and ES 2238015 A1.

3. ☐ Other:

C. ☐ The following additional information is provided for the Examiner's consideration.

IV. CROSS REFERENCE TO RELATED APPLICATION(S)

A. ☒ The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this(these) application(s) to the Examiner's attention, Applicant(s) does (do) not waive the confidentiality provisions of 35 U.S.C. § 122.

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
10/522,697	27 January 2005	Zambrana, J., <i>et al.</i>
11/722,786	25 June 2007	Lopez-Rodriguez, M., <i>et al.</i>
60/834,385	31 July 2006	Zambrana, J., <i>et al.</i>
60/834,384	31 July 2006	Lopez Rodriguez, M., <i>et al.</i>

V. THIS IDS IS BEING FILED UNDER

A. ☐ 37 C.F.R. § 1.97(b): (check only one box)

1. ☐ within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) (37 C.F.R. § 1.97(b)(1)). No fee or certification is required.

2. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or certification is required.

3. ☐ before the mailing of a first Office Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below; or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

4. ☐ before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No fee or certification is required.

B. ☒ 37 C.F.R. § 1.97(c): (check only one box)

before the mailing date of either any Final Office Action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution.

1. ☒ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

2. ☐ See the certification below. No fee is required.

C. ☐ 37 C.F.R. § 1.97(d):

after the mailing date of either a Final Office Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, yet on or before payment of the issue fee.

1. ☐ See the certification below. A fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e): (check only one box)

The undersigned hereby certifies that:

A. ☐ each item of information contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(1)). See further statement under 37 C.F.R. 1.704(d) below in section VII, if applicable; or

B. ☐ no item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(2)).

C. ☐ some of the items of information were first cited in a communication from a foreign patent office. As to this information, the undersigned hereby certifies that each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS.

VII. STATEMENT UNDER 37 C.F.R. 1.704(d)

The undersigned hereby states that:

☐ each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart application and this communication was not

received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this IDS.

VIII. PAYMENT OF FEES (check only one box, if applicable)

A. ☐ A check in the amount of \$180.00 is enclosed for the above-identified fee.

B. ☒ Please charge Deposit Account No. 08-0750 in the amount of \$180.00 for the above-identified fee. A duplicate copy of this paper is attached.


Please charge any additional fees or credit any overpayment pursuant to 37 C.F.R. § 1.16 or § 1.17 to Deposit Account No. 08-0750.

The above references are being cited only in the interest of candor and without any admission that they constitute statutory prior art, contain matter which anticipates the invention, or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art. Furthermore, this Information Disclosure Statement shall not be construed as a representation that a search has been made.

If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 08-0750.

Respectfully submitted,

By:


J. Timothy Keane
Attorney for Applicant
Reg. No. 27,808

Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, MO 63105
(314) 726-7518 (tel)
(314) 726-7501 (fax)



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 7

ATTORNEY DOCKET NO.

6102-000031/US/NP

SERIAL NO.

10/587,792

APPLICANT

Lopez Rodriguez, M., et al.

FILING DATE

31 July 2006

GROUP

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1	/K.B./	US 5137901 A	08/11/1992	United States	C07D 417/00	
2		US 6919360 B2	07/19/2005	United States	C07D 417/12	
3		US 2005/0250777 A1	11/10/2005	United States	C07D 498/02	

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
4		EP 0352613 B1	04/20/1994	Europe	C07D 417/12	X	
5		ES 2052829 T3	07/16/1994	Spain	C079D 417/12	X	
6		WO 199606846 A1	03/07/1996	PCT	C07D 487/04	X (abstract only)	
7		ES 2082727 A1	03/16/1996	Spain	C07D 487/04		X
8		ES 2094690 A1	01/16/1997	Spain	C07D 207/452	X (abstract only)	
9		WO 199735860 A1	10/02/1997	PCT	C07D 154/14	X (abstract only)	
10		ES 2109190 A1	01/01/1998	Spain	C07D 451/04		X
11		WO 199915527 A1	04/01/1999	PCT	C07D 487/04	X (abstract only)	
12	↓	ES 2129370 A1	06/01/1999	Spain	C07D 487/04		X

Examiner: /Kristin Bianchi/

Date Considered:

01/14/2009

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 7

ATTORNEY DOCKET NO.

6102-000031/US/NP

SERIAL NO.

10/587,792

APPLICANT

Lopez Rodriguez, M., et al.

FILING DATE

31 July 2006

GROUP

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
13	/K.B./	WO 199929687 A1	06/17/1999	PCT	C07D 405/14		
14		ES 2154605 A1	04/01/2001	Spain	C07D 451/04	X (abstract only)	
15		WO 2003029250 A1	04/10/2003	PCT	C07D 417/12	X	
16		ES 2199086 A1	02/01/2004	Spain	C07D 487/04	X	
17		WO 2004014915 A1	02/19/2004	PCT	C07D 487/04	X	
18		ES 2238015 A1	08/01/2005	Spain	C07D 487/04	X	
19		WO 2005075480 A1	08/18/2005	PCT	C07D 487/04		
20		EP 1674103 A1	06/28/2006	Europe	C07D 487/04		
21		WO 2006069993 A1	07/06/2006	PCT	C07D 487/04		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
22		Ambrossio, E. et al., <i>[³H]prazosin binding to central nervous system regions of male and female rats</i> , NEUROSCI. LETT. 49(1-2):193-197 (1984)
23		Titeler, M. et al., <i>Selectivity of serotonergic drugs for multiple brain serotonin receptors: Role of [³H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([³H]DOB), A 5-HT₂ agonist radioligand</i> , BIOCHEM. PHARMACOL. 36(19):3265-3271 (1987)
24	✓	Wong, D.T. et al., <i>Specific [³H]LY278584 binding to 5-HT₂ recognition sites in rat cerebral cortex</i> , EUR. J. PHARMACOL. 166(1):107-110 (1989)

Examiner:

/Kristin Bianchi/

Date Considered: 01/14/2009

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 3 of 7

ATTORNEY DOCKET NO.

6102-000031/US/NP

SERIAL NO.

10/587,792

APPLICANT

Lopez Rodriguez, M., et al.

FILING DATE

31 July 2006

GROUP

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
25	/K.B./	Clark, R.D. et al., <i>1,90Alkano-Bridged 2,3,4,5-Tetrahydro-1H-3-benzazepines with affinity for the α_2-adrenoceptor and the 5-HT_{1A} receptor</i> , J. MED. CHEM. 33(2):633-641 (1990)
26		Grossman, C.J. et al., <i>Development of a radioligand binding assay for 5-HT₁ receptors in guinea-pig and rat brain</i> , BR. J. PHARMACOL. 109:618-624 (1993)
27		De Vry, J., <i>5-HT_{1A} receptor agonists: recent developments and controversial issues</i> , PSYCHOPHARMACOLOGY 121(1):1-16 (1995)
28		Koh, J.Y. et al., <i>Potentiated necrosis of cultured cortical neurons by neurotrophins</i> , SCIENCE 268(5210):573-575 (1995)
29		Koroshetz, W.J. and Moskowitz, M.A., <i>Emerging treatments for stroke in humans</i> , TRENDS PHARMACOL. SCI. 17(6):227-33 (1996)
30		Lopez-Rodriguez, M.L. et al., <i>Novel benzimidazole-4-carboxylic acid derivatives as potent and selective 5-HT₃ receptor ligands</i> , BIOORG. MED. CHEM. LETT. 6(11): 1195-1198 (1996)
31		Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1,3-dioxoperhydroimidazo[1,5-α]pyridine: a selective 5-HT_{1A} receptor agonist</i> , J. MED. CHEM. 39(22):4439-4450 (1996)
32		Lopez-Rodriguez, M.L. et al., <i>2-[4-(o-Methoxyphenyl)piperazin-1-ylmethyl]-1,3-dioxoperhydroimidazo[1,5-α]pyridine as a new selective 5-HT_{1A} receptor ligand</i> , BIOORG. MED. CHEM. LETT. 6(6):689-694 (1996)
33		Matsuyama, S. et al., <i>Regulation of glutamate release via NMDA and 5-HT_{1A} receptors in guinea pig dentate gyrus</i> , BRAIN RES. 728(2):175-180 (1996)
34		Lopez-Rodriguez, M.L. et al., <i>Comparative receptor mapping of serotonergic 5-HT₃ and 5-HT₄ binding sites</i> , J. COMPUT.-AIDED MOL. DES. 11(6):589-599 (1997)
35		Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 2. Three-dimensional quantitative structure-activity relationships of hydantoin-phenylpiperazine derivatives with affinity for 5-HT_{1A} and α1 receptors. A comparison of CoMFA models</i> , J. MED. CHEM. 40(11):1648-1656 (1997)
36	↓	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 3.1 2-[omega-(4-aryl-piperazin-1-yl)alkyl]perhydropyrrolo-[1,2-c]imidazoles and -perhydroimidazo[1,5-α]pyridines: study of the influence of the terminal amide fragment on 5-HT_{1A} affinity/selectivity</i> , J. MED. CHEM. 40(16):2653-2656 (1997)

Examiner:

/Kristin Bianchi/

Date Considered:

01/14/2009

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 4 of 7

ATTORNEY DOCKET NO.

6102-000031/US/NP

SERIAL NO.

10/587,792

APPLICANT

Lopez Rodriguez, M., et al.

FILING DATE

31 July 2006

GROUP

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
37	/K.B./	Aguirre, N. et al., <i>MDMA ('Ecstasy') enhances 5-HT_{1a} receptor density and 8-OH-DPAT-induced hypothermia: Blockade by drugs preventing 5-hydroxytryptamine depletion</i> , EUR. J. PHARMACOL. 346(2-3):181-188 (1998)
38		Beneytez, M.E. et al., <i>Preclinical pharmacology of B-20991, a 5-HT_{1A} receptor agonist with anxiolytic activity</i> , EUR. J. PHARMACOL. 344:127-135(1998)
39		Lopez-Rodriguez, M.L. et al., <i>1-[ω-(4-Arylpiperazin-1-yl)alkyl]-3-diphenylmethylene-2,5-pyrrolidinediones as 5-HT_{1A} receptor ligands: Study of the steric requirements of the terminal amide fragment on 5-HT_{1A} affinity/selectivity</i> , BIOORG. MED. CHEM. LETT. 8:581-586(1998)
40		Nonaka, S. et al., <i>Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx</i> , PROC. NAT'L. ACAD. SCI. USA 95(5):2642-2647 (1998)
41		Suchanek, B. et al., <i>The 5-HT_{1A} receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis</i> , EUR. J. PHARMACOL. 355(1):95-101 (1998)
42		Ahlemeyer B. et al., <i>The 5-HT_{1A} receptor agonist Bay x 3702 inhibits apoptosis induced by serum deprivation in cultured neurons</i> , EUR. J. PHARMACOL. 370(2):211-216 (1999)
43		Justicia, C. and Planas, A.M., <i>Transforming growth factor-α acting at the epidermal growth factor receptor reduces infarct volume after permanent middle cerebral artery occlusion in rats</i> , J. CEREB. BLOOD FLOW METAB. 19(2):128-132 (1999)
44		Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 1. Synthesis and structure-activity relationships of new benzimidazole-4-carboxamides and carboxylates as potent and selective 5-HT₁ receptor antagonists</i> , BIOORG. MED. CHEM. 7:2271-2281 (1999)
45		Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotonergic 5-HT₁ receptors</i> , J. MED. CHEM. 42:5020-5028 (1999)
46		Lopez-Rodriguez, M.L. et al., <i>Design and synthesis of 2-[4-[4-(m-ethylsulfonylamido)phenyl]piperazin-1-yl]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole (EF-7412) using neural networks. A selective derivative with mixed 5-HT_{1A/D2} antagonist properties</i> , BIOORG. MED. CHEM. LETT. 9:1679-1682 (1999)

Examiner: /Kristin Bianchi/

Date Considered: 01/14/2009

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 5 of 7

ATTORNEY DOCKET NO.

6102-000031/US/NP

SERIAL NO.

10/587,792

APPLICANT

Lopez-Rodriguez, M., et al.

FILING DATE

31 July 2006

GROUP

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
47	/K.B./	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2,5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2,5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT_{1A} affinity/selectivity</i> , J. MED. CHEM. 42(1):36-49 (1999)
48		Lopez-Rodriguez, M.L. et al., <i>Synthesis of new (benzimidazolyl)piperazines with affinity for the 5-HT_{1A} receptor via Pd(0) amination of bromobenzimidazoles</i> , BIOORG. MED. CHEM. LETT. 9:2339-2342, 1999
49		Galter, D. et al., <i>Sequential activation of the 5-HT_{1A} serotonin receptor and TrkB induces the serotonergic neuronal phenotype</i> , MOL. CELL. NEUROSCI. 15(5):446-455 (2000)
50		Lopez-Rodriguez, M.L. et al., <i>First pharmacophoric hypothesis for 5-HT₇ antagonism</i> , BIOORG. MED. CHEM. LETT. 10:1097-1100 (2000)
51		Lopez-Rodriguez, M.L. et al., <i>Pd(0) Amination of benzimidazoles as an efficient method towards new (benzimidazolyl)piperazines with high affinity for the 5-HT_{1A} receptor</i> , TETRAHEDRON 56:3245-3253 (2000)
52		Schaper, C. et al., <i>Stimulation of 5-HT_{1A} receptors reduces apoptosis after transient forebrain ischemia in the rat</i> , BRAIN RES. 883(1): 41-50 (2000)
53		Torup, L. et al., <i>Neuroprotective effect of 8-OH-DPAT in global cerebral ischemia assessed by stereological cell counting</i> , EUR. J. PHARMACOL. 395(2):137-141 (2000)
54		Kline, A.E. et al., <i>The selective 5-HT_{1A} receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats</i> , NEUROSCIENCE 106(3) 547-555 (2001)
55		Lopez-Rodriguez, M.L. et al., <i>Computational model of the complex between GR113808 and the 5-HT₁ receptor guided by site-directed mutagenesis and the crystal structure of rhodopsin</i> , J. COMPUT.-AIDED. MOL. DES. 15: 1025-1033 (2001)
56		Lopez-Rodriguez, M.L. et al., <i>Study of the bioactive conformation of novel 5-HT₁ receptor ligands: influence of an intramolecular hydrogen bond</i> , TETRAHEDRON 57:6745-6749 (2001)
57		Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 5. Study of the physicochemical influence of the pharmacophore on 5-HT(1a)/alpha(1)-adrenergic receptor affinity: synthesis of a new derivative with mixed 5-HT(1a)/d(2) antagonist properties</i> , J. MED. CHEM. 44(2):186-197 (2001)

Examiner:

/Kristin Bianchi/

Date Considered:

01/14/2009

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 6 of 7

ATTORNEY DOCKET NO.

6102-000031/US/NP

SERIAL NO.

10/587,792

APPLICANT

Lopez Rodriguez, M., et al.

FILING DATE

31 July 2006

GROUP

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
58	/K.B./	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 6. Study of the 5-HT_{1A}/alpha(1)-adrenergic receptor affinity by classical hansch analysis, artificial neural networks, and computational simulation of ligand recognition</i> , J. MED. CHEM. 44(2):198-207 (2001)
59		Lopez-Rodriguez, M.L. et al., <i>3D-QSAR/CoMFA and recognition models of benzimidazole derivatives at the 5-HT₄ receptor</i> BIOORG. MED. CHEM. LETT. 11:2807-2811 (2001)
60		Mauler, F., et al., <i>Inhibition of evoked glutamate release by the neuroprotective 5-HT_{1A} receptor agonist BAY x 3702 in vitro and in vivo</i> , BRAIN RES. 888(1):150-157 (2001)
61		Caicoya, A.G. et al., <i>Biochemical, electrophysiological and neurohormonal studies with B-20991, a selective 5-HT_{1A} receptor agonist</i> , PHARMACOLOGY 62: 234-242 (2001)
62		Lopez-Rodriguez, M.L. et al., <i>Arylpiperazine derivatives acting at 5-HT_{1A} receptors</i> , CURR. MED. CHEM. 9:443-469 (2002)
63		Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition 5-HT₄ receptor antagonists</i> , J. MED. CHEM. 45: 4806-4815 (2002)
64		Lopez-Rodriguez, M.L. et al., <i>Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine_{1B} receptor ligands to explore the three-dimensional structure of the receptor</i> , MOL. PHARMACOL. 62:15-21 (2002)
65		Lopez-Rodriguez, M.L. et al., <i>5-HT₄ receptor antagonists: structure-affinity relationships and ligand-receptor interactions</i> , CURR. TOPICS MED. CHEM. 2:625-641 (2002)
66		Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 4. The recognition of the voluminous substituent attached to the basic amino group of 5-HT₄ receptor antagonists</i> , J. COMPUT.-AIDED MOL. DES. 17:515-524 (2003)
67		Lopez-Rodriguez, M.L. et al., <i>Design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT_{1A}/5-HT₃ ligands</i> , BIOORG. MED. CHEM. LETT. 13:3177-3180 (2003)
68		Lopez-Rodriguez, M.L. et al., <i>Design and synthesis of S-(-)-2-[[4-(naph-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2-a]pyrazine (CSP-2503) using computational simulation. A 5-HT_{1A} receptor agonist</i> , BIOORG. MED. CHEM. LETT. 13(8):1429-1432 (2003)

Examiner: /Kristin Bianchi/

Date Considered: 07/14/2009

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 7 of 7

ATTORNEY DOCKET NO.

6102-000031/US/NP

SERIAL NO.

10/587,792

APPLICANT

Lopez Rodriguez, M., et al.

FILING DATE

31 July 2006

GROUP

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
69	/K.B./	Lopez-Rodriguez, M.L. et al., <i>Optimization of the pharmacophore model for 5-HT₇ receptor antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives</i> , J. MED. CHEM. 46:5638-5650 (2003)
70		Pascual D. et al., <i>New benzimidazole derivatives: selective and orally active 5-HT₃ receptor antagonists</i> , EUR. J. PHARMACOL. 462:99-107 (2003)
71		Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 5. Design and synthesis of new benzimidazole-aryl piperazine derivatives acting as mixed 5-HT_{1A}/5-HT₂ ligands</i> , BIOORG. MED. CHEM. 12:5181-5191 (2004)
72		Lopez-Rodriguez, M.L. et al., <i>Serotonin 5-HT₇ receptor antagonists</i> , CURR. MED. CHEM.-CNSA 4:203-214 (2004)
73		Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of aryl piperazines. Part 7: Study of the influence of lipophilic factors at the terminal amide fragment on 5-HT_{1A} affinity/selectivity</i> , BIOORG. MED. CHEM. 12(6):1551-1557 (2004)
74		Delgado, M. et al., <i>Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT_{1A}, 5-HT_{2A} and 5-HT₇ receptors</i> , EUR. J. PHARMACOL. 511:9-19 (2005)
75		Lopez-Rodriguez, M.L. et al., <i>A three-dimensional pharmacophore model for 5-hydroxytryptamine₆ (5-HT₆) receptor antagonists</i> , J. MED. CHEM. 48:4216-4219 (2005)
76	↓	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of aryl piperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT_{1A}R agonists with selectivity over alpha1-adrenoceptors</i> , J. MED. CHEM. 48(7):2548-2558 (2005)

Examiner: /Kristin Bianchi/

Date Considered:

01/14/2009

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.